Multiorgan failure induced by atorvastatin [3]

American Journal of Medicine

Volumn 113, Issue 4, 2002, Pages 348-349

  Sreenarasimhaiah, Jayaprakash ^a   Shiels, Peggy ^a   Lisker Melman, Mauricio ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; ATORVASTATIN; LIVER ENZYME;

ACUTE KIDNEY FAILURE; ADULT; ANEMIA; CASE REPORT; CAUSE OF DEATH; CHOLESTATIC HEPATITIS; DRUG SAFETY; ENZYME BLOOD LEVEL; FEMALE; HEART INFARCTION; HEMODIALYSIS; HUMAN; HYPERLIPIDEMIA; INTUBATION; KIDNEY FAILURE; LABORATORY TEST; LETTER; LIVER TOXICITY; METABOLIC ACIDOSIS; MULTIPLE ORGAN FAILURE; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; PANCREATITIS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA;

AGED; DIAGNOSIS, DIFFERENTIAL; FATAL OUTCOME; FEMALE; HEPATITIS, CHRONIC, DRUG-INDUCED; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; MULTIPLE ORGAN FAILURE; PYRROLES;

EID: 0036701953     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(02)01178-6     Document Type: Letter

References (6)

1. Knopp R.H. Drug therapy drug treatment of lipid disorders. N Engl J Med. 341:1999;498-511.
2. Jimenez-Alonzo J. Atorvastatin-induced cholestatic hepatitis in a young woman with systemic lupus erythematosis. Arch Intern Med. 159:1999;1811-1812.
3. Black D. An overview of the clinical safety profile of atorvastatin, a new HMG-CoA reductase inhibitor. Arch Intern Med. 158:1998;577-584.
4. Maron D.J. Current perspectives on statin. Circulation. 101:2000;207-213.
5. Physician's Desk Reference. 54th ed. 2000;2254-2257 Medical Economics Company, Inc, Montvale, New Jersey.
6. Gonzales M.L. Atorvastatin-induced severe thrombocytopenia. [letter] Lancet. 352:1998;1284.